She points out the only categorical A1C figure reported: 73.5% on CagriSema hit 6.5% or lower from a baseline of 8.0, versus 15.9% on placebo.
Recap by typeshit. Post by Jen Can NuSH on X.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
She notes the FDA approved a change to Zepbound's labeling in October 2024, adding context to a study now circulating online.
@itsjakesjourney says Wegovy shut off his desire for alcohol. One person's account, but it lines up with growing research interest in GLP-1s for addiction.
Loading…